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Abstract 
Background: With the genetic studies having become very popular in the last years, the need for 
the creation of specific checklists, which help the authors to improve the way they write articles, 
has arisen. A large number of genetic studies focus on the MTHFR gene and its two single 
nucleotide polymorphisms (SNPs), (C677T) and (A1298C), trying to find an association between 
the aforementioned gene and Chronic Lymphocytic Leukemia.  
Aim: The purpose of the present study is to evaluate the quality of reporting of genetic association 
studies for MTHFR (rs 1801131) in Chronic Lymphocytic Leukemia using the STREGA statement 
and to perform a Meta-analysis, in order to explore the association between MTHFR (rs1801131) 
polymorphism and CLL/SLL risk. 
Methods: All of the studies, published before July 2015, were identified through computer based 
searches of the following databases, PubMed and HuGE. The articles were evaluated based on the 
STREGA statement and a Meta-analysis was performed using the ORG and the “ORGGASMA” 
software. 
Results: The results of the evaluation of quality reporting, based on STREGA statement were from 
highest to lowest: 17.04/22 for Lim et al. 2006, 14.41/22 for Nuckel et al. 2004, 11.35/22 for Rudd 
et al. 2004 and for Gra et al. 2007, 7.76/22. As far as the Meta-analysis is concerned, the p-value 
for the Q-statistic is 0.48, which is more than 0.10, so there is no significant heterogeneity between 
the studies. For this reason the Fixed effects model was selected, for MTHFR A1298C and ORG was 
found to be 0.9849 with 95% Confidence Interval (0.883-1.098). The 95% CI includes the value 
“1”, so as a result the ORG is not considered significant. 
Conclusion: Genetic articles appear to have methodological errors that could be avoided with the 
use of the recommendations given in STREGA statement. In the Meta-analysis, the MTHFR 
(rs1801131) polymorphism was not significantly associated with the risk for CLL/SLL, 
 
Keywords: STREGA, MTHFR, A1298C, SLL, CLL, chronic lymphocytic leukemia, polymorphism, 
meta-analysis, genes.  
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 13:10:15 EET - 137.108.70.7
 TABLE OF CONTENTS  
1. INTRODUTION ............................................................................................................................... 3 
1.1 Chronic lymphocytic leukemia ............................................................................................. 3 
1.2 MTHFR gene ........................................................................................................................... 4 
1.3 STrengthening the REporting of Genetic Association studies Statement ......................... 5 
AIM OF THE STUDY ............................................................................................................................... 5 
2. MATERIALS AND ΜETHODS ............................................................................................................. 6 
2.1 Literature search ......................................................................................................................... 6 
2.2 Inclusion criteria. ......................................................................................................................... 6 
2.3 Study selection ............................................................................................................................. 6 
2.4 Data Extraction ............................................................................................................................ 6 
2.5 Quality of reporting of genetic associations studies ................................................................. 7 
2.6 Statistical Analysis ....................................................................................................................... 7 
3. RESULTS ............................................................................................................................................. 8 
3.1 Published articles. ....................................................................................................................... 8 
3.2 Summary of quality of reporting ................................................................................................ 9 
3.3 Summary of study characteristics………………………………………………………………………………….10 
3.4 Association between MTHFR A1298C and CLL/SLL risk…………………………………………………10 
4. DISCUSSION ................................................................................................................................... 113 
5. REFFERENCES ................................................................................................................................. 15 
6. APPENDICES .................................................................................................................................... 17 
 
  
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 13:10:15 EET - 137.108.70.7
 1. INTRODUTION 
 
1.1 Chronic lymphocytic leukemia 
Cancer is considered to be one of the most challenging public health issues. It is estimated that the 
cancer cases and cancer deaths in 2008 were nearly 12.7 million and 7.6 million worldwide 
respectively (He et al. 2014). Leukemias are defined as a group of cancers deriving from 
hematopoietic cell lines. Disruptions of the normal function of the genes at these locations can 
cause an alteration from normal blood cell development. This can be a result of genetic 
translocations, inversions, or deletions in hematopoietic cells (Robien et al. 2003).  
The mechanism, by which leukemias cause disease, includes the accumulation of dysfunctional or 
non-differentiated leukemic cells, in the bone marrow. These cells slowly replace normal 
hematopoietic cells, causing signs and symptoms such as anemia, fatigue, bleeding, and infections 
(Robien et al. 2003). They can derive from myeloid or lymphoid cell lines, or both. The latter is 
the case in myeloid/lymphoid or mixed-lineage leukemia (MLL) (Rudd et al. 2004). 
Leukemias are categorized, depending on how fast disease is progressing, as either acute or 
chronic. There are four major forms of leukemia. A) Acute Lymphocytic Leukemia (ALL), B) Acute 
Myelogenous Leukemia (AML), C) Chronic Lymphocytic Leukemia (CLL), and D) Chronic 
Myelogenous Leukemia (CML) (Robien et al. 2003).  
The most common is considered to be chronic lymphocytic leukemia (CLL) (Rudd et al. 2004), 
which is categorized as a B-cell malignant lymphoma. The prognosis can be anywhere from good 
to bad. It tends to target more men than women, with the median age of patients at diagnosis at 
65 years (Rozman et al. 1995).  
CLL and small lymphocytic lymphoma (SLL) are considered to be the same disease at different 
stages, sharing the same immunophenotype and similar clinical courses (Zintzaras et al. 2009). 
CLL is considered to be an idiopathic condition. Despite the existence of evidence supporting a 
genetic background of the disease, no specific gene has been associated with it (Rozman et al. 
1995) (Kalil et al. 1999). 
Recently there have been more publications investigating that association. This increase can be 
explained if one considers how easily accessible genetic data have become and how much 
genotyping technology has developed (Zintzaras et al. 2009). Still, the evidence remains 
insufficient, not only due to the use of small study samples but also due to the heterogeneity of the 
populations. (Zintzaras et al. 2009) 
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 1.2 MTHFR gene 
Methylenetetrahydrofolate reductase (MTHFR) is an enzyme, whose main function is the 
catalyzation of redundant methylenetetrahydrofolate to methyltetrahydrofolate, which in turn 
plays part in the methylation of homocysteine to methionine (Goyette et al. 1994). The location of 
the gene for MTHFR (EC 1.5.1.20) is at the end of the short arm of chromosome 1 (1p36.3) (Figure 
1). 
 
        Figure 1. Location of MTHFR (http://ghr.nlm.nih.gov/gene/MTHFR) 
 
Folate plays a part in the conversion of homocysteine to methionine and in purine and pyrimidine 
synthesis. It acts as a carrier for single carbon fragments. Its primary form is 5-methyl-THF. The 
reduction of 5,10-methylene tetrahydrofolate (THF) can be catalysed in 5-methyl-THF, 
irreversibly by the 5,10 methylenetetrahydrofolate reductase (MTHFR) enzyme.  Therefore, any 
decline in the activity of MTHFR results in an increase of 5 methylenetetrahydrofolate, which in 
turn results in transfer of a methyl group converting dUMP to dTMP. This conversion causes uracil 
to be ill-placed into the DNA, which is claimed to have carcinogenic effects, such as DNA double-
strand breaks. (Rudd et al.2004) Methylation, as the conversion of dUMP to dTMP is named, has 
been associated with a variety of types of cancers. 
There are two single nucleotide polymorphisms (SNPs) that appear to tamper with MTHFR 
activity. The first appears in position 677 and is a C to T nucleotide transition (C677T) and the 
second in position 1298 and is an A to C transition (A1298C). (Gemmati et al 2007) The second 
polymorphism (A1298C) causes the replacement of glutamine to alanine at codon 49 (Robien et 
al. 2003). Some studies support that A1298C has an impact on MTHFR in homogenous individuals 
(Rudd et al.2004). 
In the present study, the MTHFR (rs 1801131) polymorphism was used. There are 2 alleles for 
the present polymorphism genetic variant, so there are the following genotypes AA, AC, CC. 
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 1.3 STrengthening the REporting of Genetic Association studies Statement  
The number of genetic studies that are being published has experienced a substantial increase 
over the last years (Little et al. 2009).  Various checklists and recommendations have been 
developed, in order to improve the quality of studies (Vandenbroucke et al. 2009), such as the 
STrengthening the Reporting of OBservational Studies in Epidemiology (STROBE) Statement for 
cross-sectional, case-control and cohort studies. For the sole purpose of focusing on the quality of 
genetic studies, an extension of the STROBE Statement called the STrengthening the REporting of 
Genetic Association studies (STREGA) Statement has been developed. The STREGA statement has 
been improved with revisions on 12 of the 22 items of the STROBE statement (Little et al. 2009).  
Genetic studies have their distinct challenges that differentiate them from other observational 
studies. These include complex gene pathways, gene-environment and gene-gene interactions. 
Many studies even suffer from methodological issues, such as inadequate reporting of results 
(Little et al. 2009). 
In order to overcome these methodological problems the STREGA statement revisions focus on 
five main topics. A) Genotyping errors B) population stratification C) modeling haplotype 
variation D) Hardy-Weinberg equilibrium (HWE) and E) replication (Little et al. 2009). 
 
AIM OF THE STUDY 
 
The purpose of the present study is to evaluate the quality of reporting of genetic association 
studies for MTHFR (rs 1801131) in Chronic Lymphocytic Leukemia using the STREGA statement 
and to perform a Meta-analysis, in order to explore the association between MTHFR (rs1801131) 
polymorphism and CLL/SLL risk. 
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 2. MATERIALS AND ΜETHODS   
 
2.1 Literature search 
All of the studies, published before July 2015, were identified through computer based searches 
of the following databases, PubMed and HuGE, using the following terms: “chronic lymphocytic 
leukemia”, “CLL”, “chronic lymphocytic leukaemia”, “chronic lymphoid leukemia”, “chronic 
lymphoid leukaemia”, “small lymphocytic lymphoma”, “SLL”, “lymphocytic lymphoma”, “gene”, 
“polymorphism”. 
 
2.2 Inclusion criteria.  
The studies included had to satisfy the following criteria:  
1) Evaluate MTHFR A1298C polymorphisms 
2) Include cases of chronic lymphocytic leukemia 
3) Are either case-control study, nested case-control study or a cohort study 
4) Are written in English 
 
Furthermore, for the studies to be included in the Meta-analysis, they had to satisfy an additional 
set of criteria. The studies had to provide all the numbers of cases and controls at each genotype 
and be of case control design exclusively. 
 
2.3 Study selection  
All of the articles were screened by title or abstract. If the inclusion criteria were satisfied, the 
article was used in the present study. Some studies used patients with different types of Non-
Hodgkin Lymphoma. Those studies were screened by reading the ‘materials and methods’ section 
of the papers. If there were patients with CLL/SLL, they were included. 
 
2.4 Data Extraction 
The data from every paper, which was relative to the subject, were summarized into a table. The 
table included all of the important information about the studies, such as the first author’s name, 
the publication year, the mean age and the range of age, the genotyping method, the ethnicity and 
the number of cases and controls. Moreover a second table, which has the frequencies of 
genotypes, is also provided. 
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2.5 Quality of reporting of genetic associations studies 
As stated above, the STREGA statement (as an extension of STROBE for genetic studies) was used 
to evaluate the quality of reporting of genetic associations studies for MTHFR (rs 1801131) in 
Chronic Lymphocytic Leukemia. The STREGA statement was used as Little et al. 2009 described 
and recommended (Little et al. 2009).  
 
2.6 Statistical Analysis  
The main purpose of the present study was to evaluate the association between MTHFR (rs 
1801131) polymorphism and CLL/SLL risk. Using the Chi-square test, it was tested, if the control’s 
genotype distribution was in Hardy Weinberg equilibrium (HWE). For the Meta-analysis of 
association of MTHFR polymorphism and CLL/SLL risk, an alternative methodology was 
performed, called the Generalized Odds Ratio (ORG). The ORG is a genetic model-free approach, 
equal to the probability of being diseased divided by the probability of being non-diseased 
(Zintzaras.2010). “ORGGASMA” software, which is available at http://biomath.med.uth.gr, was 
used to calculate the ORG and 95% Confidence Interval using either the Fixed effects model (FE) 
or the Random effects model, depending on heterogeneity (Zintzaras.2010). Q and I2 were used to 
test for homogeneity in ORGGASMA. The present study used only the Recessive model (Liao et al. 
2013) to calculate the OR, the variance of log(OR) known as theta and the 95% CI.  The results 
were presented graphically using a forest plot. Publication bias was evaluated with a funnel plot 
and Egger’s test (Lee.2015). All statistical analyses were performed using the SPSS version 21 
software.   
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 3. RESULTS   
 
3.1 Published articles. 
The purpose of the present study was to investigate the quality of reporting of genetic association 
studies for MTHFR (rs1801131) in chronic lymphocytic leukemia using the STREGA statement. In 
July 2015, a search in PubMed and HuGE databases was conducted. The search resulted in 52 
articles being identified. However, only a few of them used patients with CLL/SLL and investigated 
the MTHFR polymorphism of interest (rs1801131). As a result only 4 of them were relative to the 
study and were included in the Meta-analysis. 
      
Figure 2: Flow chart of published articles retrieved for and excluded from an assessment of MTHFR of Chronic lymphocytic leukemia. 
Table 3.1.1: Selected Studies  
Author and Year Number of study Reason 
Gra et al. 2007 1  
CLL & MHTFR A1298C Lim et al. 2006 2 
Rudd et al. 2004 3 
Nuckel et al. 2004 4 
52 Titles were found in PubMed and HuGE 
48 articles were excluded: 
• 4 articles were Meta-analysis 
• 15 articles investigated MTHFR 
(rs181133) 
• 2 articles investigated other genes 
• 1 article used Molecular biomarkers on 
CLL/SLL 
• 26 articles on NHL did not provide 
CLL/SLL phenotype 
  
4 studies were selected 
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3.2 Summary of quality of reporting  
A table with all of the STREGA statement recommendations and the positive scoring by article is 
provided (Table 3.2.1). Every positive answer is equal to one point and every negative is equal to 
zero. For some of the recommendations that have subqueries, the 1 point is divided by the number 
of the respective subqueries, but the score of every item is calculated by the sum of all of its 
subqueries’ answers. 
TABLE 3.2.1. STREGA reporting recommendations, extended from STROBE Statement and the 
recording of quality of reporting of genetic associations studies for MTHFR (A1298C) in CLL.  
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Item 
Item 
numb
er 
 
STROBE Guideline 
 
Extension for Genetic 
Association Studies (STREGA) 
Gra et al. 
2007 
Rudd et al. 
2004 
Nuckel et al. 
2004 
Lim et al.   2006 Total 
Title 
and 
Abstrac
t 
  
1 
 
(a) Indicate the study’s design with a 
commonly used term in the title or the 
abstract. 
 NO  NO NO YES 1* 
(b) Provide in the abstract an informative 
and balanced summary of what was done 
and what was found. 
 
  YES YES YES YES 4* 
 0.5™ 0.5™ 0.5™ 1™  
Title and Abstract Total Score 0.5® 0.5® 0.5® 1®  
Introduction 
Backgro
und 
rational
e 
2 Explain the scientific background and 
rationale for the investigation being 
reported. 
 YES YES YES YES 4* 
Objectiv
es  
3 State specific objectives, including any pre-
specified hypotheses. 
State if the study is the first 
report of a genetic association, 
a replication effort, or both.  
NO NO NO YES 1* 
Introduction Total 1® 1® 1® 2®  
Methods 
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 Item 
Item 
numb
er 
 
STROBE Guideline 
 
Extension for Genetic 
Association Studies (STREGA) 
Gra et al. 
2007 
Rudd et al. 
2004 
Nuckel et al. 
2004 
Lim et al.   2006 Total 
Study 
design 
4 Present key elements of study design early 
in the paper. 
 NO YES NO YES 2* 
Setting 5 Describe the setting, locations and relevant 
dates, including periods of recruitment, 
exposure, follow-up, and data collection. 
 YES YES YES YES 4* 
Particip
ants 
6 Cohort study – Give the eligibility criteria, 
and the sources and methods of selection of 
participants.  Describe methods of follow-
up. 
Case-control study – Give the eligibility 
criteria, and the sources and methods of 
case ascertainment and control selection. 
Give the rationale for the choice of cases 
and controls. 
Cross-sectional study – Give the eligibility 
criteria, and the sources and methods of 
selection of participants. 
Give information on the 
criteria and methods for 
selection of subsets of 
participants from a larger 
study, when relevant.  
NO 
 
NO YES YES 2* 
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  Cohort study – For matched studies, give 
matching criteria and number of exposed 
and unexposed. 
Case-control study – For matched studies, 
give matching criteria and the number of 
controls per case. 
      
Variabl
es 
7 (a) Clearly define all outcomes, exposures, 
predictors, potential confounders, and 
effect modifiers. Give diagnostic criteria, if 
applicable. 
 (b) Clearly define genetic 
exposures (genetic variants) 
using a widely-used 
nomenclature system. Identify 
variables likely to be 
associated with population 
stratification (confounding by 
ethnic origin). 
 
NO 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
3* 
4* 
 0.5™ 1™ 1™ 1™  
Data 
sources 
measur
ement 
  
8* 
 
(a) For each variable of interest, give 
sources of data and details of methods of 
assessment (measurement). Describe 
comparability of assessment methods if 
there is more than one group. 
 (b) Describe laboratory 
methods, including source and 
storage of DNA, genotyping 
methods and platforms 
(including the allele calling 
algorithm used, and its 
version), error rates and call 
rates. State the 
laboratory/centre where 
genotyping was done. 
Describe comparability of 
laboratory methods if there is 
more than one group. Specify 
whether genotypes were 
assigned using all of the data 
from the study simultaneously 
or in smaller batches.  
 
YES 
NO 
 
 
 
 
YES 
YES 
 
 
 
 
YES 
YES 
 
 
 
 
YES 
YES 
 
 
 
 
4* 
3* 
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0.5™ 
 
 
 
 
1™ 
 
 
 
 
1™ 
 
 
 
 
1™ 
Bias 9 (a) Describe any efforts to address potential 
sources of bias.   
(b) For quantitative outcome 
variables, specify if any 
investigation of potential bias 
resulting from 
pharmacotherapy was 
undertaken. If relevant, 
describe the nature and 
magnitude of the potential 
bias, and explain what 
approach was used to deal 
with this. 
NO 
NO 
NO 
NO 
NO 
NO 
NO 
NO 
0* 
0* 
 
 
0™ 0™ 0™ 0.5™  
Study 
size 
10 Explain how the study size was arrived at.   NO NO NO NO 0* 
Quantit
ative 
variable
s    
11 Explain how quantitative variables were 
handled in the analyses. If applicable, 
describe which groupings were chosen, and 
why. 
If applicable, describe how 
effects of treatment were dealt 
with. 
NO NO YES NO 1* 
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 Statistic
al 
method
s 
  
12 
 
 
(a) Describe all statistical methods, 
including those used to control for 
confounding. 
State software version used 
and options (or settings) 
chosen. 
NO YES YES YES 3* 
(b) Describe any methods used to examine 
subgroups and interactions. 
 NO YES YES YES 4* 
(c) Explain how missing data were 
addressed.  
 NO NO NO YES 1* 
Cohort study – If applicable, explain how 
loss to follow-up was addressed. 
Case-control study – If applicable, explain 
how matching of cases and controls was 
addressed. 
Cross-sectional study – If applicable, 
describe analytical methods taking account 
of sampling strategy. 
 NO YES YES YES 3* 
(e) Describe any sensitivity analyses.  YES NO NO NO 1* 
  (f) State whether Hardy-
Weinberg equilibrium was 
considered and, if so, how.  
NO YES YES YES 3* 
 (g) Describe any methods 
used for inferring genotypes 
or haplotypes.  
NO YES YES YES 3* 
 (h) Describe any methods 
used to assess or address 
population stratification.  
NO YES NO NO 1* 
 (i) Describe any methods used 
to address multiple 
comparisons or to control risk 
of false positive findings.  
NO NO NO YES 1* 
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  (j) Describe any methods used 
to address and correct for 
relatedness among subjects 
 
NO NO NO YES 1* 
 0.1™ 0.6™ 0.5™ 0.8™  
Material and Methods Total Score 2.1® 5.1® 5.5® 6.3®  
Results 
Particip
ants 
   
13* Report the numbers of individuals at each 
stage of the study – e.g., numbers 
potentially eligible, examined for eligibility, 
confirmed eligible, included in the study, 
completing follow-up, and analysed. 
Report numbers of individuals 
in whom genotyping was 
attempted and numbers of 
individuals in whom 
genotyping was successful. 
NO 
 
NO NO YES 1* 
(b) Give reasons for non-participation at 
each stage. 
 NO NO NO NO 0* 
(c) Consider use of a flow diagram. 
 
 NO NO NO NO 0* 
 0™ 0™ 0™ 0.33™  
Descrip
tive 
data 
 
  
14* 
 
(a) Give characteristics of study 
participants (e.g., demographic, clinical, 
social) and information on exposures and 
potential confounders. 
 
Consider giving information 
by genotype.  
YES YES YES YES 4* 
(b) Indicate the number of participants 
with missing data for each variable of 
interest. 
 YES NO NO NO 0* 
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 Cohort study – Summarize follow-up time, 
e.g. average and total amount. 
 - - - - - 
 
 
 
 
 
0.5™ 0.5™ 0.5™ 0.5™  
Outcom
e data 
15 * Cohort study-Report numbers of outcome 
events or summary measures over time. 
Report  outcomes 
(phenotypes) for each 
genotype category over time 
     
Case-control study – Report numbers in 
each exposure category, or summary 
measures of exposure. 
Report numbers in each 
genotype category 
 
YES YES YES YES 4* 
Cross-sectional study – Report numbers of 
outcome events or summary measures. 
Report outcomes 
(phenotypes) for each 
genotype category 
     
Main 
results 
16 (a) Give unadjusted estimates and, if 
applicable, confounder-adjusted estimates 
and their precision (e.g., 95% confidence 
intervals). Make clear which confounders 
were adjusted for and why they were 
included. 
 NO YES NO YES 2* 
(b) Report category boundaries when 
continuous variables were categorized. 
 NO NO NO YES 1* 
(c) If relevant, consider translating 
estimates of relative risk into absolute risk 
for a meaningful time period. 
 NO NO NO NO 0 
  (d) Report results of any 
adjustments for multiple 
comparisons.  
 
NO NO YES NO 1* 
 0™ 0.25™ 0.25™ 0.25™  
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 Other 
analyse
s 
17 Report other analyses done – e.g., analyses 
of subgroups and interactions, and 
sensitivity analyses. 
 YES YES YES YES 4* 
   (b) If numerous genetic 
exposures (genetic variants) 
were examined, summarize 
results from all analyses 
undertaken. 
YES YES YES YES 4* 
  (c) If detailed results are 
available elsewhere, state how 
they can be accessed. 
 
NO NO NO YES 1* 
 0.66™ 0.66™ 0.66™ 1™  
 
Results Total Score 
2.16® 2.75® 2.41® 2.74®  
Discussion 
Key 
results 
18 Summarize key results with reference to 
study objectives. 
 YES YES YES YES 4* 
Limitati
ons 
19 Discuss limitations of the study, taking into 
account sources of potential bias or 
imprecision. Discuss both direction and 
magnitude of any potential bias. 
 NO NO YES YES 2* 
Interpr
etation   
20 Give a cautious overall interpretation of 
results considering objectives, limitations, 
 YES YES YES YES 4* 
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 multiplicity of analyses, results from similar 
studies, and other relevant evidence. 
General
izability  
21 Discuss the generalizability (external 
validity) of the study results. 
 NO NO YES YES 2* 
Other Information 
Fundin
g 
22 Give the source of funding and the role of 
the funders for the present study and, if 
applicable, for the original study on which 
the present article is based. 
 NO NO YES YES 2* 
 
Discussion Total score 
2® 2® 5® 5®  
Total score 7.76¥ 11.35¥ 14.41¥ 17.04¥  
 
* Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies. 
* A positive answer erns on point and a zero for a negative answer.  Then summarized all the numbers (0,1) an the line.  
®   A positive answer erns on point and a zero for a negative answer.  Then summarized all the numbers (0,1) an the column. 
¥ Summarized all the total score from Title and Abstract, Materials and Methods, Results and Discussion.  
™ The sum of the answer from subqueries. A positive answer erns on point and a zero for a negative answer. 
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By section: 
• Title or Abstract and Introduction: Lim et al. 2006 scored higher, having more positive 
points than the others. Nuckel et al. 2004, Rudd et al. 2004 and Gra et al. 2007 all did not provide 
a common term for the study design. 
• Materials and Methods: Lim et al. 2006 scored better than the others with 6.3/9. They had 
more information about the study design and the methods. Nuckel et al. 2004 and Rudd et al. 2004 
were at the same level scoring 5.5/9 and 5.1/9 respectively. But Gra et al. 2007 did not provide 
very detailed information concerning the patient sample and the statistical analysis, therefore the 
score was only 2.1/9.  
• Results: All the articles were at the same level. Their scores were between 2.16/5 and 
2.75/5. Gra et al. 2007 scored the lowest (2.16). Nuckel et al. 2004 followed with 2.41/5. Rudd et 
al. 2004 and Lim et al. 2006 scored 2.75 and 2.74/5 respectively. 
• Discussion: Nuckel et al. 2004 and Lim et al. 2006 had a perfect score of 5/5, as opposed 
to the other two studies that scored 2/5.   
The total scores, from highest to lowest, were: 17.04/22 for Lim et al. 2006, 14.41/22 for Nuckel 
et al. 2004, 11.35/22 for Rudd et al. 2004 and for Gra et al. 2007 7.76/22. 
 
3.3 Summary of study characteristics  
Table 3.2.2 summarizes all of the study design characteristics including country, ethnicity, 
genotyping technology, sample size, percentage of males, mean age or range of age and conclusion 
by article. The study design of all of the four studies was diagnostic case-control, with the cases 
being patients who had already been diagnosed with CLL/SLL. The ethnicity was mainly 
Caucasian, except for one study, in which it was mixed. The sample size ranged from 111 to 1141 
and 32 to 949 for cases and controls respectively. TaqMan is used as a genotyping method in 2 out 
of 4 the studies. In one study (Nuckel et al. 2004) no information about the average age or gender 
of patients or controls was provided.  
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Table 3.2.2: Summary of studies characteristics. 
Authors and  
year 
Country Study Design Ethnicity Genotyping 
Method 
Mean Age Males Sample Size 
 
Gra et al. 2007 
 
Russia 
 
Case Control 
 
Caucasian 
 
Hybrridization 
 
53 
(31-83) 
 
57.8% 
 
159 cases  
 177 controls 
 
Lim et al. 2006 
 
USA 
 
Case Control 
 
 
Mixed 
 
Taqman 
 
(20-74) 
 
55% cases 
53% controls 
 
1141cases  
 949 controls 
 
Rudd et al. 2004 
 
UK 
 
Case Control 
 
Caucasian 
 
Taqman 
 
61 (21-97)& 
59(26-93)& 
60(21-91) 
 
69.3% 
 
832 cases  
 886 controls 
 
Nuckel et al. 2004 
 
Germany 
 
Case Control 
 
Caucasian 
 
PCR-RFLP 
 
- 
 
- 
 
111 cases  
32 controls 
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 3.4 Association between MTHFR A1298C and CLL/SLL risk 
Table 3.4.1: Hardy –Weinberg equilibrium 
Authors Controls X2 p-value 
AA AC CC 
Gra et al. 
2007 
81 82 14 1.16 0.27 
Lim et al. 
2006  
461  393  81 0.135  0.83  
Nuckel et al. 
2004 
55 40 7 0.029 0.94 
Rudd et al. 
2004 
412 389 85 0.4 0.62 
 
All the controls distribution were in line with the Hardy-Weinberg equilibrium. 
Table 3.4.2: Frequencies of MTHFR A1298C polymorphism. 
 
 
The frequency distribution of MTHFR A1298C polymorphism genotype, the result from Chi-
square (X2), p-value and the degree freedoms are shown in Table 2.3.2. All the p-value were not 
less than the 10% point of the x2 distribution with 2 df and as a result none of the studies indicated 
statistically significant association. 
If Q is less than the 10% point of the x2 distribution, with 4-1=3 df, there is no significant 
heterogeneity across studies. In more detail, the results were Q= 2.47 with p-value = 0.48 and I2= 
0.0. Overall, the p-value for the Q-statistic is 0.48, which is more than 0.10, so there is no significant 
heterogeneity between the studies. The decision, which model must be used, the Fixed or the 
Random effects model, depends on heterogeneity. The chosen model is the Fixed effects model for 
MTHFR A1298C (ORG = 0.9849; 95%CI: 0.883-1.098) because the heterogeneity is not significant. 
 
Authors 
 
Cases CLL/SLL 
 
Controls 
 
X2 
 
p-value  
AA AC CC ALL AA AC CC ALL 
Gra et 
al. 2007 
39 38 6 83 81 82 14 177 0.057 0.97 
Rudd et 
al. 2004 
397 363 72 832 412 389 85 886 7.557 0.75 
Lim et 
al. 2006 
540 480 104 1124 461 393 81 935 0.419 0.81 
Nuckel 
et al. 
2004 
51 48 12 111 55 40 7 102 1.817 0.4 
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 The 95% CI includes the value “1”, as a result the ORG is not considered significant. So according 
to the Meta-analysis of GAS, it is concluded that, with the present data, the MTHFR (rs 1801131) 
polymorphism is not associated with CLL/SLL disease.  
The number of studies was very limited, and only one study used Mixed population. All of the rest 
used Caucasians. As a result it is not possible to perform subgroup analysis for different 
ethnicities.  
Table 3.4.2: Recessive model 
Study 
 
 
Patients CLL/SLL Control OR 95% CI 
CC Total CC Total 
Gra et al. 
2007 
6 83 14 177 0.91 (0.34 -2.45) 
Rudd et al. 
2004 
72 832 85 886 0.89 (0.64 -1.24) 
Lim et al. 
2006 
104 1124 81 935 1.07 (0.79 -1.46) 
Nuckel et al. 
2004 
12 111 7 102 1.65 (0.62 -1.36) 
 
The forest plot of GAS (based on the recessive model) is presented below: 
 
                                            Figure 1. The forest plot of GAS. The x-axis is OR (95% CI) and y-axis are the studies. 
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 Publication bias  
The funnel plot is a simple scatter plot, which is able to identify publication bias in meta-analysis, 
but it does not provide an extended prediction (Lau et al. 2006). In our case it is not easy to 
determine whether the funnel plot is asymmetric, which would indicate publication bias. The 
variable depicted in the y-axis is the precision (1/SE) (Lee.2015). 
 
                                            Figure 2. The funnel plot of GAS. The x-axis is theta (Θ) and y-axis is Precision (1/SE) 
In the present study Egger’s test was used (linear regression). If the p-value is greater than 0.05, 
it is not possible to reject the null hypothesis, which is that: there is not publication Bias. The p-
value is equal to 0.598, greater than 0.05, so the publication bias does not appear to be statistically 
significant (Egger et al. 1997).  
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 4. DISCUSSION   
 
The purpose of the present study is to conduct a meta-analysis for the association of the MTHFR 
(rs1801131) with CLL/SLL, after having investigated the quality of reporting of genetic 
association studies for MTHFR (rs1801131) in chronic lymphocytic leukemia using the STREGA 
statement. In July 2015, a search in PubMed and HuGE databases was conducted. A total of 52 
articles were found, with only 4 of them being relative to the subject. The limited number of 
eligible studies is due to the fact that only few of them use patients with CLL/SLL and investigate 
the MTHFR polymorphism of interest (rs1801131). 
The results of evaluation of quality reporting, based on STREGA statement, from highest to lowest, 
were: 17.04/22 for Lim et al. 2006, 14.41/22 for Nuckel et al. 2004, 11.35/22 for Rudd et al. 2004 
and for Gra et al.2007, 7.76/22.  
The results of quality reporting   are related to the impact factor of the journal, where the article 
was published.  Lim et al. 2006 had the greatest score (17.04) with the impact factor of BLOOD, in 
which it was published, being 10.452 (2014). Nuckel et al. 2004 scored (14.41/22) with the 
impact factor of LEUKEMIA being 10.431(2014), Rudd et al. 2004 scored 11.35/22 with the 
impact factor of the CANCER EPIDEMIOLOGY, BIOMARKERS & PREVENTION being 4.125 and 
finally, Gra et al. 2007 had a score of 7.76/22 with the impact factor of AMERICAN GOURNAL OF 
HEMATOLOGY being 3.798. Consequently, it is evident that there is a remarkable relation between 
the score each article receives from the STREGA and the Impact factor of the journal, in which the 
article is published. However it must be noted that the impact factors stated above are for the year 
2014 and the articles were published from 2004 to 2007. The most recent article, which was 
published in 2007 had the lowest score, while the article with the highest score was published in 
2006. Thus the publication year does not appear to be related to the quality reporting. 
Overall, only one of articles reported the study design in the title or abstract and used the usual 
term to describe it. This is a major methodological gap, because it is not easy to quickly identify 
the type of the study. It is very important to report that all of the studies were case – controls. 
Moreover, there was not any explanation on how they calculated the sample size.  
In addition Little et al. 2009, stated that there is a distinction between laboratories (high and 
lower throughput) causing them to have different error rates. However, not on a single article was 
there any information about the state of laboratory, that could affect the results and influence the 
error rate.  
Furthermore, no information was given about whether the articles’ data were available at another 
source.  Only Lim et al. 2006 mentions that there were missing data. All the other articles did not 
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 provide information neither about the missing data nor about whether all samples were 
genotyped successfully. Also, only Lim et al. 2009 recorded information about a potential bias. 
Ιn the meta-analysis, the MTHFR (rs1801131) polymorphism was not significantly associated 
with the risk for CLL/SLL, which is consistent with results by Zintzaras et al. 2009. It was not 
possible to conduct subgroup analysis by race, because the number of the studies was limited. The 
inadequate number of studies made it impossible to use the Harbord test to identify the effect of 
study size.  Furthermore, it was not possible to use solely the high-quality studies in the Meta-
analysis, due to that same limitation. Publication bias was not significant, in the relevant articles.  
The limitations of this study should be addressed. There was only a very limited number of studies 
that were eligible for our evaluation. Moreover, all of the articles were published before 2009, 
which is the year the STREGA statement became available. This is the most probable reason, why 
only a few of them cover the items of the STREGA checklist. Another limitation is that we confined 
our search to only two databases and a third database (e.g. EMBASE) was not used.  
Regarding the scoring, it could also slightly vary among different evaluators, depending on their 
personal point of view. This process could introduce a potential bias, which could be restricted if 
the articles were also assessed by a second evaluator.  
The STREGA statement, was only used by Ghazali et al. 2012 and Terrazzino et al. 2013 as a 
replacement of PICO for meta-analysis and Data Extraction. No articles evaluating the reporting 
quality of studies with the same or related subject to this study, were found. It should be 
emphasized that there is no available information, about a standard threshold that dictates that a 
study is of poor or good quality. Therefore, for our evaluation, it was necessary to compare and 
contrast the four articles with each other. 
In conclusion, genetic articles appear to have methodological errors that could be avoided with 
the use of the recommendations given in the STREGA statement. The necessity of a document that 
elaborates on the STREGA recommendations, same as the STROBE Explanation and Elaboration 
document (Vandenbroucke et al. 2007), is undeniable. Only after the improvement of quality and 
quantity of publications, there will be clear evidence of the possible genetic associations with CLL. 
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 Figure 3 Abstract (Rudd et al. 2004) 
Figure 4 Introduction (Rudd et al. 2004) 
6. APPENDICES  
6.1 Title: MTHFR Polymorphisms and Risk of Chronic Lymphocytic Leukemia  
Authors: Matthew F. Rudd, Gabrielle S. Sellick, Ruth Allinson, Estella Matutes, Daniel 
Catovsky and Richard S. Houlston.  
Cancer Epidemiol Biomarkers Prev 2004;  13(12).  
 
6.1.1 Title and Abstract 
Item 1a: There is not the usual term in the 
title or the abstract. 
Item 1b: There is a balanced summary 
because is not separate the background, 
design, patients, measurements, results, 
limitations and conclusions. 
 
 
 
 
 
 
 
6.1.2 Introduction
Item 2: There is scientific background of the 
study that provides important context for 
readers. (Vandenbroucke et al., 2007) 
Item 3: There is not any information if this is 
the first report of a genetic association in 
CLL. There is only one important key-point, 
that the MTHFR affects the risk of a number 
of malignancies including ALL. 
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6.1.3 Methods 
Item 4: Case-control study (in the end of 
introduction) 
Item 5: United Kingdom, Royal Marsden Hospital 
NHS and National Cancer Research Network Trial 
1999-2002 and 1999-2002.  
 
Controls were the spouses of patients with 
nonhematologic malignancies and were selected to 
closely match the age and sex of the cases. None of 
the controls had a personal history of CLL or other 
malignancy. 
Item 6a: There is not any information on the criteria 
and methods for selection of subsets of participants 
from a larger study. Patients with nonhematologic 
malignancies and were selected to closely match the 
age and sex of the cases 
Item 7a: To determine whether the C677T and 
A1298C polymorphisms of MTHFR are associated 
with risk of CLL. 
Item 7b: Clearly define the genetic variant and to 
define the population stratification have used the 
distribution of genotypes in controls was tested for a 
departure from Hardy-Weinberg equilibrium. Also all     
the patients are British Caucasians.  
Item 8a: Controls selected to be match the age and sex of 
the cases. The method was used to detection MTHFR 
genotype use described.  
Item 8b: Describe the laboratory method (PCR), include 
source and storage of DNA, genotyping method and 
platform.  There is no information about error rates, call 
rates, state of laboratory.  
Figure 5 Materials and Methods (Rudd et al. 
2004) 
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 Item 9a: Controls selected to be match the age and sex of the cases. No other information.  
Item 9b: No information. 
Item 10: Not information about study size
Item 11: No information about treatment.  
Item 12a: STATA version 7.0 (Stata 
Corporation, College Station, TX) POWER 
version 1.30  
Item 12b: logistic regression (adjusting for age 
and sex) X2 test 
Item 12 c: Not information about missing data 
Item 12d: Controls selected to be match the age 
and sex of the cases. 
Item 12e: No information of any sensitivity 
analysis. 
Item 12f: The controls were tested for HWE. 
Item 12g: An unequal distribution of haplotype 
frequencies between cases and controls was 
tested for by means of the X2test, where L1 is 
the likelihood of cases and controls analyzed 
together and L0 the sum of the individual 
likelihoods. 
Item 12h: To test for population stratification, 
the distribution of genotypes in controls was 
tested for a departure from Hardy Weinberg 
equilibrium. The observed frequencies in the 
controls for both polymorphisms of MTHFR 
were in accordance with Hardy-Weinberg laws 
of equilibrium, providing no evidence of 
population stratification within the data set. 
 
Item 12i: No information 
Item 12j: No information 
 
 
Figure 6 Statistical Analysis (Rudd et al., 2004) 
Figure 7 Results and Discussion (Rudd et al., 2004) 
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 6.1.4 Results 
Item 13: Numbers of individuals in whom genotyping was successful: 832 cases and 886 controls. 
No information about missing data. Not information about no participation at each stage and flow 
diagram.  
Item 14: The frequencies in our study (and in 
the meta-analysis) are CC/AA, 12% (15%); 
CC/AC 22% (22%); CC/CC, 10% (8.5%); CT/AA, 
22% (22%); CT/AC, 22% (20%); CT/CC, 0% 
(0.25%); TT/ AA, 12%(11%); TT/AC, 0% 
(0.46%); and TT/CC, 0%(0.03%). No 
information about missing data.
Item 15: Table 1 
Item 16a: Associated 95% CIs associated with each 
genotype. Adjustment for age and sex made no 
significant difference to findings hence only 
unadjusted ORs are presented95% confidence 
interval. No information about confounders. 
Item 16b: No information 
Item 16c: No information 
Item 16d: Adjustment for age and sex made no 
significant difference to findings hence only 
unadjusted ORs are presented???(multy analysis) 
Item 17a: Provide no statistically significant 
evidence that MTHFR plays a role in development of 
CLL, we cannot entirely exclude a small effect in risk 
of CLL associated with MTHFR variants. Moreover, 
as there is evidence of a gene-environment effect 
with respect to folate metabolism and cancer risk, it 
is possible that polymorphisms of MTHFR may 
mediate CLL risk in the context of a low-folate diet. 
The distribution of haplotypes was not significantly 
different between cases and controls 
Item    17b: The results were summarized in a table.  
Item 17c: No information
 
Figure 8 Associations of MTHFR and CLL (Rudd et. 
al., 2004) 
Figure 9 Results and Discussion No 2 (Rudd et al.,2004 
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 6.1.5 Discussion  
Item 18: Provide no statistically significant evidence 
that MTHFR plays a role in development of CLL, we 
cannot entirely exclude a small effect in risk of CLL 
associated with MTHFR variants. Moreover, as there is 
evidence of a gene-environment effect with respect to 
folate metabolism and cancer risk, it is possible that 
polymorphisms of MTHFR may mediate CLL risk in the 
context of a low-folate diet. The distribution of 
haplotypes was not significantly different between 
cases and controls. 
Item 19: No information about a potential bias. 
Item 20: Provide no statistically significant evidence that 
MTHFR plays a role in development of CLL, we cannot 
entirely exclude a small effect in risk of CLL associated 
with MTHFR variants. Moreover, as there is evidence of a 
gene-environment effect with respect to folate 
metabolism and cancer risk it is possible that 
polymorphisms of MTHFR may mediate CLL risk in the 
context of a low-folate diet. The frequency of the MTHFR 
C677T and A1298C polymorphisms in the general 
population has been recently reported in a meta-analysis 
of 16 studies providing data on 5,389 individuals. The 
frequencies of both polymorphisms detected in our 
study are in close agreement with this report. 
Item 21: No information  
Item 22: No information about conflicts of interest. 
 
  
Figure 10 Results and Discussion No 3 (Rudd et al., 
2004) 
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6.2. Title: Methylenetetrahydrofolate reductase (MTHFR) gene 677C4T and 1298A4C 
polymorphisms are associated with 
differential apoptosis of leukemic B cells in 
vitro and disease progression in chronic 
lymphocytic leukemia  
Editors: H Nuckel, UH Frey, J Du¨ rig, U 
Du¨hrsen and W Siffer.  
 
6.2.1 Title and Abstract   
Item 1a: There is not the usual term in the title or the 
abstract 
Item 1b: There is a balanced summary because is not 
separate the background, design, patients, measurements, results, limitations and conclusions. 
 
6.2.2 Introduction  
Item 2: There is scientific background of the study 
that provides important context for readers. 
(Vandenbroucke et al., 2007) 
Item 3: There is not any information if this is the first 
report of a genetic association in CLL. There is only 
one important key-point, that the MTHFR affects the 
risk of a number of malignancies including ALL. 
 
6.2.3 Methods  
Item 4: No use of normal term of study design.  
Item 5: The period was August 2001 and October 2003. 
All the patients were Caucasian. There is not information 
about location. 
Figure 11 Abstract (Nuckel et al., 2004) 
 
Figure 12 introduction (Nuckel et al. 2004 
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 Item 6a: Indications for treatment were based on 
standard criteria by Cheson (1996) 
Item 6b: Age-matched controls, 111 CLL cases and 92 
controls.  
Item 7a: Retrospective study of 111 CLL patients 
designed to evaluate the potential of the MTHFR 
677C4T and 1298A4C gene polymorphisms as a 
prognostic factor for the natural course of B-CLL in 
patients with Binet stage A. In addition, we report the 
results of a multivariate analysis of the genotype data 
with other important prognostic factors in B-CLL. We 
investigated which cellular phenotype might 
contribute to the observed association. To study the 
impact of prognostic factors for a first-line therapy, a 
multivariate Cox regression analysis was performed. 
Item 7b: Genetic variant is clearly define. All the 
patients were Caucasian.  
Item 8a: Following the manufacturer’s instructions and 
MTHFR genotypes were determined by PCRRFLP as 
described by Semenza et al., 2003 and Skiloba et al., 
1999. 
Item 8b: Describe the laboratory method (PCR), 
include source and storage of DNA, genotyping method 
and platform. There is not information about error 
rates, call rates, state of laboratory.  
Item 9a: No other information.  
Item 9b: No information about a potential bias.   
Item 10: No information about study size.  
Item 11: Out of a total of 111 patients, 53 (47%) had 
previously received chemotherapy, and almost 34 
patients of the 53 CLL (64%) patients received a 
second therapy. In first-line therapy, 36 patients 
received chlorambucil, 14 patients fludarabine and 
three patients the CHOP regime. 
 
Figure 13 Introduction (Nuckel et al., 2004) 
Figure 14 Materials and Methods (Nuckel et al. 
2004) 
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 Item 12a: SPSS 11.0 and Ott (http://linkage. 
rockefeller.edu/ott/linkutil.htm)  
Item 12b: Kaplan–Meier method and compared using the 
log-rank test. Subgroups was performed using Student’s t-
test for continuous variables and the X2 test for categorical 
data. Comparison of apoptosis rates dependent on 
genotypes was performed using the ANOVA and Mann–
Whitney test, respectively. Differences were regarded 
significant at P=0.05.To study the impact of prognostic 
factors for a first-line\therapy, a multivariate Cox 
regression analysis. 
Item 12 c: Not information about missing data. 
Item 12d: Age-matched controls. 
Item 12e: No information of any sensitivity analysis. 
Item 12f: The controls were tested for HWE. 
Item 12g: Haplotype analysis and control for deviation 
from the Hardy–Weinberg equilibrium (HWE) were 
conducted with the public domain programs EH and 
HWE by J Ott  
Item 12h: Not information about stratification. 
Item 12i: The impact of prognostic factors for a first-line 
therapy, a multivariate Cox regression analysis was 
performed. 
 Item 12j: No information 
 
6.2.4 Results  
Item 13: Analyzed 111 patients with CLL and 92 age-
matched controls for the MTHFR 677C4T and MTHFR 
1298A4C gene polymorphism. But no information about 
missing genotyping. No information about non-
participation at each stage or a flow diagram.  
Figure  15 Statistical Analysis (Nuckel et al.2004) 
Figure 16 Results (Nuckel et al., 2004) 
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 Item 14: Table 1. 
Item 15: Table 2. 
Item 16a: 95% confidence interval. No 
information about confounders. 
Item 16b: No information. 
Item 16c: No information. 
Item 16d: Multivariate (Cox) analysis for 
independent prognostic factors. Both MTHFR 
polymorphisms are independent factors if only 
adjusted for gender and age. 
Item 17a: Correlation of MTHFR 1298A4C gene 
polymorphism with clinical and laboratory data in 
CLL patients. Haplotype analysis of MTHFR 
677C4T and MTHFR. Multivariate (Cox) analysis 
for independent prognostic factors. Correlation of 
the MTHFR 677C4T and MTHFR1298A4C 
polymorphisms with clinical and laboratory data 
in ZAP-70-negative CLL 1298A4C gene 
polymorphism. Increased spontaneous apoptosis 
in B cells from CLL patients with the MTHFR 
677CC and MTHFR1298AC/CC polymorphisms 
Item    17b: The results were summarized in tables.  
Item 17c: No information. 
 
6.2.5 Discussion  
Item 18: Recently, it was suggested that polymorphisms at positions 677 and 1298 of the MTHFR 
gene are associated with reduced susceptibility for acute lymphocytic leukemia. Comparing 
frequencies of MTHFR genotypes in CLL patients’ vs healthy controls, no significant differences 
were observed. Therefore, MTHFR polymorphisms are unlikely to influence the susceptibility to 
develop CLL. A strong linkage disequilibrium of these two polymorphisms was confirmed here.  
Figure 17 Table (Nuckel et al. 2004 
Figure 18 Table (Nuckel et al 2004) 
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 Item 19: Finally, some limitations of our study must be 
discussed. The major confinement resides in the limited 
number of cases that was available for analysis. This 
becomes especially evident in haplotype analysis and when 
subgroups are analyzed, for example, ZAP-70-negative 
patients. Moreover, a common problem of all smaller 
genetic association studies resides in potential 
unrecognized selection bias, which cannot be excluded 
definitively.  
Item 20: The data generate novel hypotheses regarding the 
role of MTHFR gene variants in the progression of CLL, 
which will have to be confirmed in independent studies. 
This will help to clarify whether especially those 
associations reported here which just escaped statistical 
evidence presumably due to limited sample size can be 
corroborated. It would be of special interest to determine a 
potential association of MTHFR variants with folate and 
homocysteine status. Some limitations of our study must be 
discussed. The major confinement resides in the limited 
number of cases that was available for analysis. This 
becomes especially evident in haplotype analysis and when 
subgroups are analyzed, for example, ZAP-70-negative 
patients. Moreover, a common problem of all smaller 
genetic association studies resides in potential 
unrecognized selection bias, which cannot be excluded 
definitively. 
Item 21: The data generate novel hypotheses regarding the 
role of MTHFR gene variants in the progression of CLL, 
which will have to be confirmed in independent studies. 
Item 22: Financial support by Essen Medical School IFORES 
program. 
Figure 19 Discussion (Nuckel et al. 2004) 
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 6.3 Title: Gene-nutrient interactions among determinants of folate and one -carbon 
metabolism on the risk of non-Hodgkin lymphoma: NCI-SEER Case-Control Study  
Authors : Unhee Lim, Sophia S. Wang, Patricia Hartge, Wendy Cozen, Linda E. 
Kelemen, Stephen Chanock, Scott Davis,  Aaron Blair,  Maryjean Schenk, Nathaniel 
Rothman and Qing Lan   
 
6.3.1 Title and Abstract   
Item 1a: There is a usual term in the 
title or the abstract, Case – Control. 
Item 1b: There is a balanced 
summary because is not separate 
the background, design, patients, 
measurements, results, limitations 
and conclusions. Also the 
investigator gives an overview of 
what is known on the topic and the 
gaps in current knowledge. 
(Vandenbroucke et al., 2007) 
 
6.3.2 Introduction  
Item 2: There is scientific 
background of the study that 
provides important context for 
readers. (Vandenbroucke et al., 
2007) 
Item 3: Previously reported that 
the highest quartiles of vitamin B6 
and methionine intake were 
associated with about 50% lower 
risk of NHL overall and that folate 
intake was inversely associated 
with diffuse large B-cell lymphoma 
(DLBCL).This is the first 
investigation of NHL that examined potential gene-nutrient interactions involving one-carbon 
metabolism. 
Figure 20 Abstract 9lim et al. 2006) 
Figure 21 Introduction (Lim et al 2006) 
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6.3.3 Methods 
Item 4: Case – Control. The study 
desing is early in the paper, in the end 
of the Introduction which is 
aceptable by Vandenbroucke et al., 
2007. 
Item 5: Population: women and 
men aged 20 to 74 years. Period: 
July 1998 through June 2000. On all 
NHL cases from local SEER 
registries classified the 
histologically confirmed cases into 
subtypes of DLBCL, follicular 
lymphoma, and small lymphocytic 
lymphoma (SLL) according to the 
International Classification of 
Diseases-Oncology. Population 
controls who were aged 20 to 74 years, HIV negative, and with no history of NHL. Location: NCI 
and SEER centers of Detroit, Iowa, Los Angeles, and Seattle 
Item 6: There is not any information on the criteria and methods for selection of subsets of 
participants from a larger study. Population controls who were aged 20 to 74 years, HIV negative, 
and with no history of NHL were identified among the study area residents via random-digit-
dialing and Health Care Financing Administration (Medicare) file. The cases were newly-
diagnosed and human immunodeficiency virus (HIV)–negative NHL cases were identified from 4 
Surveillance, Epidemiology, and End Results (SEER). The controls frequency matched to cases on 
sex, age and race but not study centers, to have the most parsimonious estimates. No information 
about number per case. We adjusted for the matching factors of age (continuous), sex, and race, 
but not study centers, to have the most parsimonious estimates. 
Item 7a: They investigated genetic susceptibility of selected one-carbon metabolism enzymes and 
their interaction with diet using a comprehensive assessment of the metabolic pathways.  
Item 7b: The genetic variant using the widely used nomenclature. All nutrients except alcohol 
were adjusted for total energy intake by the nutrient-density method. Regression models of folate, 
vitamin B6, and methionine were adjusted for each other for potential confounding. Additional 
adjustments for energy intake and other nutrients did not materially change the risk estimates.  
Figure 22 Material and Methods (Lim et al 2006) 
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 Item 8a: There is information about genotyping is available by Wang et al., 2006 and dietary 
assessment. 
Item 8b: Describe the laboratory method, include source and storage of DNA, genotyping method 
and platform. No any other information about call rates, error rates and state of laboratory.  
Item 9a: Our findings based on post diagnostic assessment of diet need to be replicated in 
prospective data with less influence of potential bias associated with recalled diet and selective 
participation of healthier controls. Although this is one of the largest polymorphism studies to 
date regarding one-carbon metabolism, it was still limited to examine gene-nutrient interactions. 
Item 9b: No information. 
Item 10: No information about study 
size. 
Item 11: No information about 
treatments.  
Item 12a: SAS/Genetics (version 9.1.3; 
SAS Institute, Cary, NC) to assess 
Hardy-Weinberg equilibrium and 
linkage disequilibrium among SNPs 
from the same gene. 
Item 12b: Wilcoxon nonparametric test for continuous variables and chi-squared tests for 
categoric variables to compare the descriptive characteristics of cases and controls with genetic 
information, separately by the availability of diet information, controls with and without diet 
information. And comparing heterozygote and homozygous variant (or less prevalent genotype) 
to homozygous wild-type (or more prevalent genotype) in logistic regression models 
Item 12 c: All participants who were genotyped and the subgroup who had both genotype and diet 
information. 
Item 12d: Controls selected to be match the age and sex of the cases. 
Item 12e: No information of any sensitivity analysis. 
Item 12f and g: Hardy-Weinberg equilibrium and linkage disequilibrium among SNPs from the 
same gene. We explored haplotype analyses for genes with or more polymorphisms but did not 
detect any stronger associations, and therefore, present the findings from individual 
polymorphism analyses. 
Item 12h: No information 
ΕFigure 23 Statistical analysis (Lim et al 2006) 
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 Item 12i: To evaluate the probability of false-positive associations, we computed the false 
discovery rate (FDR), which controls the proportion of false positives out of all significant findings 
using the P values from the regression of score variables (ie, the trend test, also referred to as the 
additive model) using SAS software: we considered FDR less than 0.2 as noteworthy. 
 Item 12j: We also computed the false-positive report probabilities (FPRPs)45 using prior 
probabilities ranging from 0.1 to 0.001 based on gene selection criteria described in “Genotyping” 
and considered values below a criterion of 0.2 noteworthy as recommended in the initial 
description of the method. 
 
6.3.4 Results 
Item 13: Genotyping was successful in 96% to 100% of DNA samples, similarly in blood- and 
buccal cell–based samples. From 1321 and 1057, the 1141 cases and the 949 controls who were 
genotyped successfully. There is not any information about non participation at each stage and 
flow diagram.  
Item 14a: Table  
Item 14b: From 1321 and 1057, the 1141 cases and the 949 controls who were genotyped 
successfully. 
Item 15: Table 1 
Item 16a: However, we did not observe any independent interaction of folate when 
simultaneously adjusted for vitamin B6. We adjusted for the matching factors of age (continuous), 
sex, and race, but not study centers, to have the most parsimonious estimates. 95% confidence 
interval. All nutrients except alcohol were adjusted for total energy intake by the nutrient-density 
method. The main associations and gene-nutrient interactions were not confounded by other risk 
factors in combined and individual subtype analyses. 
Item 16c: No information 
Item 16d: Additional adjustments for energy intake and other nutrients did not materially change 
the risk estimate.(??? is thiw from a amultiple analysis) 
Item 17a: All participants who were genotyped and the subgroup who had both genotype and diet 
information. The genotype-NHL association of polymorphisms that exhibited a significant main 
effect, linear trend, or interaction with a nutrient among people with both genotype and diet data. 
Main effects among all genotyped data (Table S2) showed similar association patterns and 
identified additional variants in FTHFD, MTHFS, and MTR for significant associations or trends 
with NHL. We examined interactions between all genetic variants and nutritional determinants, 
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 specifically vitamin B6 and methionine that were previously found protective against NHL.27 We 
detected a number of significant interactions. 
Item    17b: The results were summarized in a table.  
Item 17c: No information.  
  
6.2.5 Discussion  
Item 18: The discussion summarized key results.   
Item 19: The findings of gene-nutrient interactions have similar limitations that were discussed 
in our previous study of dietary associations. The population-based design of this case-control 
study might have reduced selection bias compared with hospital-based recruitment.  The 
population-based design of this case-control study might have reduced selection bias compared 
with hospital-based recruitment. Our findings based on post diagnostic assessment of diet need 
to be replicated in prospective data with less influence of potential bias associated with recalled 
diet and selective participation of healthier controls. 
Item 20: Our study is the first to show an interaction between a variant in MTHFR and one-carbon 
nutrients, specifically methionine, in relation to NHL. This finding emulates the previous 
epidemiologic reports of such interactions in colorectal cancer. 
 
Item 21: Lastly, this line of investigation could also have implications for prognosis and survival 
of NHL. However, these results require replication in further large studies as well as pooled 
analyses. 
Item 22: Conflict-of-interest disclosure: The authors declare no competing financial interests.  
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 6.4 Title: Polymorphisms in xenobiotic-metabolizing genes and the risk of chronic 
lyphocytic leykemia and non Hodghin’s lymphoma in adult Russian patients  
Authors: Olga A. Gra, Andrey S. Glotov, Eugene A. Nikitin, Oleg S. Glotov, Viktoria E. 
Kuznetsova, Alexander V. Chudinov,  Andrey B. Sudarikov, and Tatyana V. Nasedkina  
Am J Hematol. 2008;83(4):279–287. 
 
6.4.1 Title and Abstract   
Item 1a: There is not the usual 
term in the title or the 
abstract 
. 
Item 1b: There is a balanced 
summary because is not 
separate the background, 
design, patients, 
measurements, results, 
limitations and conclusions. 
 
6.4.2 Introduction   
Item 2: There is scientific 
background of the study 
that provides important 
context for readers. 
(Vandenbroucke et al., 
2007)  
 
Item 3: There is not any 
information if this is the 
first report of a genetic 
association in CLL.  
Figure 24 Abstract (Gra et al.2007) 
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6.4.3 Methods 
Item 4: No information 
about study design early in 
the paper.  
 
Item 5: Seventy-six 
patients with clinical 
diagnosis of T-cell NHL and 
eighty three patients with 
B-CLL were included in the 
study. All patients were 
diagnosed with 
lymphomas at the National 
Hematology Research Center of Russian Academy of Medical Sciences. Diagnosis was done 
according to the WHO classification (1997).  The control group included 177 healthy donors. 
Blood was taken at the blood transfusion center of the National Hematology Research Center. All 
patients and healthy donors were residents of European part of Russia.  
Item 6: There is not any information on the criteria and methods for selection of subsets of 
participants from a larger study.  
Item 7a: Association between main polymorphic genetic variants of metabolizing enzymes, which 
process environmental carcinogens or play key role in intracellular methylation, and individual 
susceptibility to such malignant diseases as T-cell NHL and B-CLL in a Russian population. 
Item 7b: All patients and healthy donors were residents of European part of Russia. 
Item 8a: The details of methods of assessment.  
Item 8b: Describe the laboratory method, include source and storage of DNA, genotyping method 
and platform. There is not information about error rates, call rates, state of laboratory.  
Item 9a: No information.  
Item 9b: Not information about a potential bias.   
Item 10: Not information about study size. 
Item 11: No information about treatment.  
Item 12a: GraphPad InStat software, USA,  
   Figure 25 Introduction (Gra et al. 2007) 
        Figure  26 Methods (Gra et al.2007) 
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 Item 12b: Hardy-Weinberg equilibrium was tested using the standard X2 test, Fisher test 
Item 12 c: Not information about missing data 
 
Item 12d: No information. 
Item 12e: No information of any sensitivity 
analysis. 
Item 12f: The controls were tested for HWE. 
Item 12g: No information. 
Item 12h: No information. 
Item 12i: No information. 
Item 12j: No information.  
 
6.4.4 Results 
Item 13: 83 B-CLL and 76 cases T-CLL and 177 
controls. No information about missing data. No 
information about no participation at each stage 
and flow diagram.  
 
Item 14: Table. No information about missing data.  
Item 15: Table  
Item 16a: 95% confidence interval. No 
information about confounders or 
adjustment.  
       Figure 27 Statistical analysis (Gra et al.2007) 
Figure 28 Results (Gra et al. 2007) 
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Item 16b: No information 
Item 16c: No information 
Item 16d: No information  
Item 17a: Distribution of 
metabolizing genes genotypes. 
Combined analysis for CYP1A1 
and GSTM1 loci. Sex differences 
in the occurrence of 
polymorphic variants of the 
metabolizing system genes. 
Item 17b: The results were 
summarized in a table.  
Item 17c: No information  
 
6.4.5 Discussion  
Item 18: The article summarize key 
results by gene.  
Item 19: No information 
Item 20: Provide no statistically 
significant evidence that MTHFR plays 
a role in development of CLL, we 
cannot entirely exclude a small effect in 
risk of CLL associated with MTHFR 
variants. Moreover, as there is evidence 
of a gene-environment effect with 
respect to folate metabolism and 
cancer risk, it is possible that 
polymorphisms of MTHFR may 
mediate CLL risk in the context of a 
low-folate diet. 
Item 21: No information  
           Figure 29 Table (Gra et al. 2007) 
Figure 29 Discussion (Gra et al. 2007) 
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 Item 22: No information about conflicts of interest. 
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